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Protection of calves by a prefusion-stabilized bovine RSV F
vaccine
Baoshan Zhang1, Lei Chen1, Chiara Silacci2, Michelle Thom3, Jeffrey C. Boyington1, Aliaksandr Druz1, M. Gordon Joyce1,
Efrain Guzman3, Wing- Pui Kong1, Yen-Ting Lai1, Guillaume B. E. Stewart-Jones1, Yaroslav Tsybovsky4, Yongping Yang1,
Tongqing Zhou1, Ulrich Baxa4, John R. Mascola1, Davide Corti2,5, Antonio Lanzavecchia2,6, Geraldine Taylor3 and Peter D. Kwong1
Bovine respiratory syncytial virus, a major cause of respiratory disease in calves, is closely related to human RSV, a leading cause of
respiratory disease in infants. Recently, promising human RSV-vaccine candidates have been engineered that stabilize the
metastable fusion (F) glycoprotein in its prefusion state; however, the absence of a relevant animal model for human RSV has
complicated assessment of these vaccine candidates. Here, we use a combination of structure-based design, antigenic
characterization, and X-ray crystallography to translate human RSV F stabilization into the bovine context. A “DS2” version of bovine
respiratory syncytial virus F with subunits covalently fused, fusion peptide removed, and pre-fusion conformation stabilized by
cavity-ﬁlling mutations and intra- and inter-protomer disulﬁdes was recognized by pre-fusion-speciﬁc antibodies, AM14, D25, and
MPE8, and elicited bovine respiratory syncytial virus-neutralizing titers in calves >100-fold higher than those elicited by post-fusion
F. When challenged with a heterologous bovine respiratory syncytial virus, virus was not detected in nasal secretions nor in
respiratory tract samples of DS2-immunized calves; by contrast bovine respiratory syncytial virus was detected in all post-fusion-
and placebo-immunized calves. Our results demonstrate proof-of-concept that DS2-stabilized RSV F immunogens can induce highly
protective immunity from RSV in a native host with implications for the efﬁcacy of prefusion-stabilized F vaccines in humans and for
the prevention of bovine respiratory syncytial virus in calves.
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INTRODUCTION
Bovine respiratory syncytial virus (bRSV) is a member of the
Paramyxoviridae family that is responsible for the majority of
respiratory disease in cattle annually, resulting in considerable
morbidity and losses approaching $1 billion per year.1–3 bRSV is
genetically and antigenically related to human RSV (hRSV),2 which
is responsible for over 3 million hospitalizations for severe
respiratory illness in young children and the elderly each year4–6
and for which no licensed vaccine is available. Although hRSV
vaccines have been evaluated in mouse, cotton rat, and non-
human primate (NHP) animal models, hRSV is only semipermissive
in these animals and thus does not authentically represent natural
infection. By contrast, bRSV infection in calves provides an
opportunity to monitor RSV pathogenesis and RSV vaccine
effectiveness in a natural host.7
Like infants, young calves are particularly vulnerable to bRSV,
even in the presence of moderate levels of maternal antibodies,8
with prevalence rates of up to 70% in the ﬁrst year of life.3
Although several licensed vaccines are available for bRSV, none
are fully effective: low levels of maternal antibodies against bRSV
can mitigate vaccine response in calves;8, 9 inactivated bRSV
vaccines may enhance disease;10, 11 and live vaccines have the
potential to exacerbate bRSV disease if administered
intramuscularly in the presence of a concurrent bRSV infection.12
By contrast, recombinant subunit-based vaccines do not pose risks
associated with live viruses, but do provide an opportunity to
generate highly effective and targeted immune responses. They
also have potential advantages in terms of ease and speed of
manufacturing, quality control of purity, and long term stability.
The most potently neutralizing RSV antibodies identiﬁed thus far
target the pre-fusion (pre-F) form of the RSV fusion (F) glycopro-
tein,13, 14 a type I fusion machine comprising a trimer of disulﬁde-
bonded F2 and F1 heterodimers, which is responsible for virus entry
and membrane fusion.15, 16 The pre-F form of RSV F is metastable
and spontaneously undergoes structural rearrangements to the
post-fusion (post-F) form, which no longer presents epitopes for
many potently neutralizing antibodies. We recently employed
structure-based design to engineer thermostable versions of the
pre-F hRSV F glycoprotein,17, 18 which preserve the pre-F
conformation and the associated target epitopes for highly potent
neutralizing monoclonal antibodies (mAbs) such as AM14 and D25
(refs.19, 20). These immunogens were subsequently observed to
elicit high levels of neutralizing antibodies in immunized mice and
NHPs.17, 18 Since the F glycoprotein of bRSV has greater than 80%
sequence identity with that of hRSV2 (Supplementary Fig. 1), we
hypothesized that bRSV F could be stabilized in an analogous way
to create a similarly potent bRSV vaccine. We, therefore, transferred
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the hRSV F mutations referred to as DS-Cav1 (ref. 17), single chain
(sc) alterations (sc9 and sc9-10) (ref. 18), and interprotomer
disulﬁdes (Q98C Q361C, A149C Y458C, and N183GC N428C)18 to
equivalent positions in multiple strains of bRSV to create bRSV F
trimer immunogens stabilized in the pre-F state (Fig. 1a–c).
Evaluation of the immunogenicity of these immunogens in both
mice and calves resulted in high-titer neutralizing responses, with
heterologous bRSV challenge in calves revealing protection from
viral replication, lung inﬂammation, and clinical signs of disease—
with no evidence of vaccine-associated disease enhancement—an
important milestone in the development of an effective bRSV
subunit vaccine. In addition, the high titer protective response
elicited by the prefusion-stabilized F in calves bodes well for the
elicitation of similar high titer response in humans immunized with
similarly stabilized F immunogens.
RESULTS
Design and initial characterization of bRSV F immunogens
The RSV F glycoprotein is conserved between bRSV and hRSV,
with sequence identities of ~80% (ref. 2) (Fig. 1b, d, Supplemen-
tary Fig. 1 and Supplementary Table 1), and multiple F-directed
antibodies can neutralize both hRSV and bRSV.21–24 Based on the
success of our prior engineering of pre-F hRSV F trimer,17 we
modiﬁed bRSV F to create thermostable pre-F trimers. A disulﬁde
between residues 155 and 290 (DS) along with cavity-ﬁlling
mutations S190F and V207L (Cav1) and a C-terminal T4-phage
ﬁbritin trimerization domain (foldon) were incorporated into bRSV
F from seven different strains to make bovine versions of DS-Cav1
(ref. 17) (bDS-Cav1s) (Fig. 1a, b and Supplementary Table 2), which
included cleavable C-terminal His and Strep tags for puriﬁcation.
Upon expression in Expi293F cells only three of the seven bDS-
Cav1s (strains 391-2, ATue51908, and RB94, respectively)
expressed at greater than 0.5 mg/l of culture (Supplementary
Table 2). All three of these bDS-Cav1s were recognized by pre-F-
speciﬁc mAbs D25 (ref. 20) and MPE8 (ref. 21) as well as by mAb
motavizumab (Mz)25 (Supplementary Table 2).
To enhance immunogenicity, we next sought to optimize bDS-
Cav1 thermostability. To minimize the number of designs
evaluated, we selected two RSV strains (391-2 and RB94) to
optimize initially, with the intent to introduce the best mutations
from the ﬁnal set into the third strain, ATue51908. Previous
investigations18, 26–29 of type I fusion machines have indicated
that removal of the cleavage site to create sc variants can improve
pre-F stability. Furthermore, the introduction of interprotomer
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Fig. 1 Translation of pre-F hRSV F stabilization to bRSV F. a Structural model of a pre-F hRSV F trimer stabilized by DS-Cav1 mutations (PDB ID
4MMU).17 One monomer is depicted by a blue ribbon model with the four DS-Cav1 mutations shown by red stick models outlined by red
squares. The other two monomers are depicted by gray surface representations. b Sequence variation between hRSV strain A2 and eight
different bRSV strains is mapped (orange surface representation) onto a blue ribbon model of one monomer of a DS-Cav1 pre-F RSV F trimer
colored as in a. c The locations of the DS-Cav1 mutations (red), the sc linkage (green) and interprotomer disulﬁde stabilization mutations
(green) introduced into bovine RSV F protein are indicated by boxed stick models for one RSV F monomer. In b and c, the other two monomers
of the trimer are shown as gray surface representations. d Phylogenetic tree for human (blue) and bovine (orange) RSV F proteins. Names
shown indicate the virus strain or isolate with study usage shown in parentheses. GenBank accession numbers for all strains used in this study
are shown in Supplementary Table 1
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disulﬁde bonds (DS2) has been observed to enhance both stability
and immunogenicity of hRSV F immunogens.18 Therefore, with a
focus on these two aforementioned types of stabilizations, 90
variants of bDS-Cav1 were designed, all of which employed an sc
topology and 32 of which contained an interprotomer disulﬁde
(DS2 variants). Additionally, many of the 90 designs incorporated
internal cavity-ﬁlling mutations, core residues from hRSV F for
increased stability, and additional sites of N-linked glycosylation to
mask irrelevant epitopes.
All 90 bDS-Cav1 designs were evaluated for expression and
antigenic recognition by mAbs D25, MPE8 and Mz in a 96 well-
microplate transient transfection format.17 Each design was scored
by summing enzyme-linked immunosorbent assay (ELISA) read-
ings for the pre-F-speciﬁc mAbs D25 and MPE8 (Supplementary
Tables 3 and 4). The top three-scoring DS2 designs (DS2-v1, DS2-
v5, and DS2-v3) and the top two-scoring 391-2 and RB94 sc
designs without interprotomer disulﬁdes (sc-v1 and sc-v4) were
selected for additional evaluation (Supplementary Tables 3 and 4).
To expand the dimensions of our search for optimal immunogens,
we mixed and matched DS2 interprotomer disulﬁdes (Q98C
Q361C, A149C Y458C, and N183GC N428C) and sc formats (sc9
and sc9-10) from the top ﬁve-scoring designs and added the
ATue51908 strain to generate additional designs for a total of nine
constructs, which were expressed in 1 liter Expi293F cultures
(Supplementary Table 5). The sc designs sc9 and sc9-10 differed
only in two residues, with a GS linker replacing F2F1 sites of
cleavage and fusion residues 106–144 or 104–144, respectively.18
Of these nine designs, the two sc-only variants gave 7–9-fold
higher expression yields compared to the other variants
(Supplementary Table 5). However, size exclusion chromatogra-
phy (SEC) indicated their respective molecular sizes were larger
than expected, suggesting unfolding or aggregation. We, there-
fore, chose three of the remaining ﬁve DS2 designs (each with sc
topology and added interprotomer disulﬁdes) with the highest
yield (Supplementary Table 5) for immunogenic, antigenic,
physical, and structural characterizations. Additionally, as bench-
marks, we used the DS-Cav1 variant of each of the three strains
and also the post-F form of each of the three strains (the latter
created by removing the RSV F fusion loop residues 137–146), as
previously described.30 Altogether, the sc-DS2, DS-Cav1 and post-F
immunogens of each of the three strains totaled nine ﬁnal
immunogen constructs.
All nine of these constructs gave expression yields of 2–5mg/l
except for DS2-v35 (0.24 mg/l) and RB94 DS-Cav1 (0.76 mg/l)
(Table 1), and the post-F forms consistently gave the highest
expression (3–5mg/l). After puriﬁcation on nickel and Strep-Tactin
afﬁnity columns, and subsequent cleavage of C-terminal afﬁnity
tags, all nine immunogens behaved well when analyzed by SEC.
Post-F forms eluted at slightly larger sizes than pre-F forms due to
their elongated shape,20, 30 and pre-F forms all eluted with peaks
consistent with trimer formation (Supplementary Fig. 2a, b).
Antigenic characteristics of bRSV F immunogens
The antigenicity of each puriﬁed immunogen was evaluated with
biolayer interferometry to assess recognition by the antigenic site
Ø-directed mAb D25 (ref. 20), antigenic site II-directed mAb Mz25,
31 and quaternary-speciﬁc mAbs AM14 (ref. 19) and MPE8 (ref. 21)
(Table 1). The three pre-F-speciﬁc mAbs, D25, MPE8, and AM14,
recognized all six immunogens containing pre-F stabilizing
mutations, conﬁrming stabilization of their pre-F conformations.
Moreover, recognition by the quaternary-speciﬁc mAbs MPE8 and
AM14 substantiated the formation of native-like trimers. In
contrast, these mAbs did not recognize any of the post-F
immunogens. As expected, Mz recognized all nine immunogens
since its site II epitope is not affected by pre- and post-F
conformational changes. D25 recognized the pre-F immunogens
with afﬁnities ranging from 0.4–420 nM, suggesting that antigenic T
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site Ø may be adversely affected by some of the stabilizing
mutations. The three DS-Cav1-only immunogens which also had
the least number of mutations had the highest afﬁnity for D25.
Notably, all mAbs except for D25 recognized the pre-F immuno-
gens with nanomolar afﬁnity (0.2–12.8 nM) even though these
mAbs were elicited by hRSV.
Physical characteristics of bRSV F immunogens
We next assessed the stability of puriﬁed immunogens by
subjecting them to extremes of temperature, pH, and osmolarity
as well as cycles of freeze-thaw and quantifying their subsequent
recognition by D25 (for pre-F) or Mz (for post-F) (Table 1). All nine
immunogens were observed to generally tolerate pH and
osmolarity extremes and freeze-thaw cycles, consistent with data
reported for hRSV DS-Cav1 (ref. 17). The three DS-Cav1-only
immunogens, 391-2 DS-Cav1, ATue51908 DS-Cav1 and RB94 DS-
Cav1, were most susceptible to physical extremes and lost 25–60%
of their D25 reactivity upon exposure to high (3M) osmolarity.
Curiously, the majority of immunogens actually increased
reactivity to D25 or Mz after exposure to high pH. Not surprisingly,
all three post-F immunogens, were stable at higher temperatures
as measured by Mz afﬁnity. Although none of the DS-Cav1-only
immunogens were able to antigenically survive exposure to 70 °C,
consistent with that observed for hRSV F pre-F-stabilized
immunogens,17, 18 all three of the DS2 immunogens tolerated
exposure to high temperature.
Structural characteristics of bRSV F immunogens
To further conﬁrm the pre- and post-F conformations of the
engineered bRSV F immunogens, we examined them by negative
stain electron microscopy (EM), followed by reference-free two-
dimensional (2D) class averaging of the images (Supplementary
Fig. 2c). As expected, each of the pre-F immunogens displayed
bulb-like trimer structures with a short stem-like structure at one
end, whereas the post-F immunogens displayed longer and more
slender structures, each of which was consistent with known
crystal structures of pre- and post-F hRSV F.17, 20, 30, 32
The crystal structures of two pre-F-stabilized bRSV F immuno-
gens, ATue51908 DS-Cav1 and DS2-v1 were determined to 2.65
and 3.50 Å resolution, respectively (Supplementary table 6).
ATue51908 DS-Cav1 crystallized in a monoclinic lattice not
previously observed with hRSV F immunogens. The overall
structure of ATue51908 DS-Cav1 was similar to that of hRSV DS-
Cav1 (PDB ID 4MMU)17 with a root mean square deviation (rmsd)
of 1.0 Å for 437 Cα atoms excluding residues 209–215 in a
membrane distal loop adjacent to antigenic site Ø (Fig. 2a). In this
crystal form, the appended C-terminal foldon trimerization
domain was visible in the electron density map, although its
threefold axis was tilted by ~17 degrees relative to the threefold
axis of bRSV pre-F due to crystal packing (Fig. 2a). The introduced
DS and S190F mutations showed strong electron density, while
V207L showed weaker but detectable electron density (Fig. 2a).
The DS2 immunogen DS2-v1 crystallized in the cubic lattice
commonly observed with hRSV F pre-F immunogens and, like
ATue51908 DS-Cav1, its structure was similar to hRSV DS-Cav1
with an rmsd of 1.1 Å for 435 Cα atoms. Although side chains for
the DS-Cav1 mutations were not clearly apparent in the electron
density, partly due to the 3.50 Å resolution of the structure, the
DS2 interprotomer 98C-361C disulﬁde and nearby sc linker
showed traceable electron density (Fig. 2b). We observed the
98C-361C disulﬁde bond to cause a local distortion of the α1 helix
(in which 98C is located), although the local structure surrounding
361C was unperturbed. Comparison of the two bRSV pre-F-
stabilized structures at the backbone level revealed high-structural
similarity with an rmsd of 0.9 Å between 434 equivalent Cα atoms
excluding the F2F1 linker region. The greatest structural differ-
ences between the hRSV and bRSV pre-F immunogens were
observed in residues 206–215 at the apical loop between α4 and
α5 near antigenic site Ø (Fig.2a, b, left panels), which is also the
region of highest sequence divergence (only ~50% identity)
between the two species (Supplementary Fig. 1). These structural
and sequence difference may explain the lower-binding afﬁnity of
D25 to bRSV pre-F (Table 1) relative to hRSV pre-F.17 Overall, the
structural analysis conﬁrmed the similarity of bRSV and hRSV pre-F
structures, with subtle differences in speciﬁc regions, including a
loop near antigenic site Ø.
Immunogenic characterization of bRSV F immunogens in mice
To evaluate immunogenicity, each of the nine bRSV F immuno-
gens was used to immunize a group of 10 CB6F1/J mice. Each
immunogen dose comprised 10 μg of protein adjuvanted with 50
μg of polyinosinic:polycytidylic acid (Poly I:C). Mice were primed
and boosted intramuscularly at weeks 0 and 3, respectively.
Analysis of week 5 sera revealed geometric mean reciprocal EC50
neutralization titers of 6880–11,453 for pre-F immunogen-
immunized mice, which were 33- to 55-fold higher (P < 0.0001)
than the titers (geometric mean 100–210) observed for the post-F
immunogen-immunized mice (Fig. 3a and Supplementary Table 7).
Neutralization titers elicited from pre-F-immunized mice were
82–110-fold greater than the calibrated protective titer of 100
(ref. 17). Although DS2-v1 elicited the highest titers (geometric mean
11,453), all of the pre-F immunogen-elicited titers were statistically
comparable with each other. Thus the 1000-fold difference in D25
mAb-binding afﬁnities observed between various pre-F immuno-
gens (Table 1) did not appear to impact the neutralization titers of
elicited sera. To gauge the overall immunogenicity of each
immunogen, the sera binding response to pre-F and post-F
immunogens was assessed by ELISA (Supplementary Fig. 3a). Similar
to the neutralization results, the binding titers of pre-F elicited sera
to the six pre-F immunogens were statistically comparable to each
other with geometric mean end point-binding titers ranging from
4687 to 100,323. Intriguingly, sera from DS2-v1-immunized mice
displayed the lowest titers for pre-F immunogen even though it had
the highest titers of neutralizing antibodies. As expected, sera
elicited by pre-F immunogens displayed lower-binding titers to post-
F immunogens.
Immunogenic characterization of bRSV F immunogens in calves
To investigate the effectiveness of pre-F-stabilized RSV F vaccines
in bRSV-seronegative calves, we selected the highly stable DS2
immunogen (DS2-v1), which in mice elicited the highest
neutralization titers (geometric mean reciprocal EC50 11,453). As
controls we chose post-F 391-2 and used phosphate-buffered
saline (PBS) to immunize a placebo group. Groups of ﬁve 3–6-
week-old male calves (Supplementary Table 8) were immunized
twice at weeks 0 and 4, and sera were collected 2 weeks after each
immunization. Each injection consisted of 50 μg protein in 0.6 ml
PBS adjuvanted with 1.4 ml of an oil-in-water adjuvant ISA 71G.
The reciprocal EC50 neutralization titers from the DS2-immunized
calves were observed to increase exponentially at weeks 2, 4, and
6 relative to week 0, resulting in a ﬁnal geometric mean titer of
56,055 2 weeks after the boost (Fig. 3b and Supplementary
Table 9). At week 8, 4 weeks after the boost, titers dropped to a
geometric mean of 21,849. In contrast, by week 8, post-F
immunogen elicited minimal titers (geometric mean 172) within
the same range as two of the saline control-immunized calves
(141 and 505, respectively), which may have had maternally-
derived serum antibodies at the start of the study. Results from
ELISA analysis of sera from DS2-immunized calves mirrored the
neutralization titers with binding titers steadily increasing and
then slightly decreasing from weeks 6 to 8 (Supplementary
Fig. 3b). As expected, sera from post-F-immunized calves followed
a similar trend, reaching geometric mean titers approximately 3.0
and 3.8-fold lower than DS2 by weeks 6 and 8, respectively. It is
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Fig. 2 Crystal structures of pre-F-stabilized bRSV F immunogens. a Crystal structure of bRSV F ATue51908 DS-Cav1 depicted by a Cα-worm
representation color-coded by atomic mobility factors, with thick, red worm for ﬂexible regions and thin, blue worm for more rigid regions.
Atomic level details are shown in insets on the right with stick representations and 2Fo-Fc electron density (blue) for regions that were mutated
to stabilize the pre-F conformation. The upper left inset shows a ribbon superposition of the antigenic site Ø region of ATue51908 DS-Cav1
(lime) with the structure of hRSV F DS-Cav1 (gray; PDB ID 4MMU).17 b Crystal structure of the DS2 immunogen bRSV F DS2-v1, depicted as in a
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also clear from the neutralization data (Fig. 3b) that post-F elicited
signiﬁcantly lower levels of neutralizing antibodies. Not surpris-
ingly, sera elicited by DS2 immunogen displayed lower-binding
titers to post-F immunogen, and post-F-elicited sera recognized
both pre- and post-F with comparable titers (as observed with
hRSV DS-Cav1 immunization in NHPs).17 Results from a competi-
tion ELISA showed that the week 6 sera from DS2-immunized
calves competed with the broadly neutralizing mAbs AM14, D25,
RSD5 (ref. 21), MPE8 and palivizumab (Pz),25 suggesting that
antigenic sites Ø, II, III, and V were all targeted33 (Supplementary
Fig. 4). Although the mAb Mz showed considerably less
competition than the other antigenic site II mAb, Pz, its high
34.6 pM afﬁnity25 for RSV F likely limited sera competition. As
expected, sera from post-F-immunized calves competed to a
much lower extent with the pre-F-speciﬁc mAbs, AM14, RSD5, and
MPE8, and did not compete with D25. Interestingly, two mAbs
compatible with post-F RSV F, Mz and Pz, also competed to a
much lower extent with post-F-elicited sera. This suggests that a
minority of the post-F-elicited sera was directed against site II.
Overall, the results in calves demonstrate the striking superiority
of the pre-F stabilized DS2-immunogen vs. post-fusion F, with pre-
F-induced neutralizing titers more than 100-fold higher than post-
F-induced neutralizing titers by week 6.
bRSV challenge of immunized calves
Next, all calves were challenged by intranasal and intratracheal
routes with the heterologous Snook strain of bRSV, 4 weeks after
the boost. Calves were monitored daily for clinical signs of disease
and for viral titers in the nasopharynx for 6 days after challenge. At
day 6 after challenge, calves were euthanized and bronchoalveolar
lavage (BAL) and lung biopsies from three regions of the lung
were obtained to determine viral titers, neutrophil inﬁltration, and
the extent of microscopic and macroscopic lesions. Remarkably,
calves vaccinated with DS2 had no detectable bRSV viral titers in
nasopharyngeal secretions (Fig. 4a and Supplementary Table 10).
No detectable bRSV titers were observed from a postmortem lung
wash, samples of tracheal epithelium, right apical, right cardiac or
left cardiac regions of the lung (Fig. 3d and Supplementary
Table 11). In contrast, peak nasopharyngeal virus titers 6 days post
challenge ranged from 1.81 to 2.70 log10 pfu/ml in post-F and PBS
vaccinated calves (Supplementary Table 10). Likewise, virus was
isolated post mortem from BAL cells of all of the post-F-
immunized and PBS-immunized calves with the greatest extent
of lung virus replication in the PBS-immunized control animals
(Fig. 4d). Thus, all DS2-immunized calves were protected from
bRSV viral replication in both the upper and lower respiratory
tracts. Furthermore, four out of ﬁve of the DS2-immunized calves
were also protected from clinical signs of disease, lung inﬂamma-
tion and macroscopic lung lesions (Fig. 4b, c, Supplementary Fig. 5
and Supplementary Tables 12–14). Clinical scores, based mainly on
differences in respiratory rate (RR) and body temperature, were
minimal for most of the pre-F- and post-F-immunized calves.
Scores trended higher for the PBS-immunized controls, but were
not signiﬁcantly different from the other two groups (Supple-
mentary Tables 12–13). However, both RR and body temperature
increased in all PBS-immunized calves, 6 days after bRSV
challenge, whereas the RR increased in only two post-F-
immunized and one pre-F-immunized calves at this time
(Supplementary Fig. 5a). Although the one calf in the pre-F-
immunized group that had developed a raised RR and body
temperature also exhibited signs of lung inﬂammation, the
geometric mean number of cells observed in the BAL, the
percentage of polymorphonuclear neutrophils (PMNs) in BAL, and
the percentage of macroscopic lung lesions were all statistically
lower than in the placebo group (Fig. 4b, c and Supplementary
Tables 12–14). The post-F-immunized calves displayed intermedi-
ate levels of lung inﬂammation. Although the extent of
b
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macroscopic lung lesions in the post-F-immunized calves was less
than that observed in the placebo group, the percentage of PMNs
in BAL was similar to that seen in BAL from calves in the placebo
group. Microscopic lung lesions in the placebo group, 6 days post
challenge, were typical of bRSV bronchiolitis and alveolitis and
were characterized by epithelial necrosis and hypertrophy of
bronchiolar epithelium bronchiolitis, bronchiolar exudate contain-
ing desquamated epithelial cells, neutrophils and macrophages,
and thickening of alveolar walls due to inﬁltration by mononuclear
cells and granulocytes (Supplementary Fig. 6c). In addition to
bronchiolitis and alveolitis, peribronchiolar lymphoreticular hyper-
plasia were seen in three of the post-F-immunized calves
(Supplementary Fig. 6b). In contrast, bronchiolitis and alveolitis
were absent from all but one of the DS2-immunized calves, and
the histopathology was essentially restricted to a peribronchiolar
lymphoreticular hyperplasia (Supplementary Fig. 6a).
DISCUSSION
The development of safe and effective hRSV and bRSV vaccines
continues to be a priority.2, 15, 34 For both human infants and
calves, vaccines need to surmount similar hurdles of activating
very young immune systems and overcoming vaccine inhibition
due to the presence of maternal antibodies. Currently, there is no
licensed hRSV vaccine, and bRSV vaccines continue to suffer from
issues of effectiveness.3 The antigenic and genetic similarities
between hRSV and bRSV and the need for an authentic animal
model for hRSV present a unique opportunity to evaluate
stabilized pre-F vaccine effectiveness for both diseases in a bovine
animal model. Unlike the semipermissive rodent and NHP animal
models for hRSV currently in use, bRSV infects the bovine host and
engages the innate and adaptive immune systems in a completely
native manner, allowing for robust, authentic challenge.2, 7
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In this study, we stabilized the bRSV F glycoprotein trimer in its
pre-F conformation by transplanting pre-F-stabilizing mutations
previously designed for hRSV F17, 18 into bRSV F. Despite high-
structural similarity and high-sequence identities of greater than
80% between hRSV and bRSV F glycoproteins, transplantation was
not trivial. Out of seven bRSV strains evaluated for DS-Cav1
transplantation, only three expressed at levels high enough to
permit characterization. Furthermore, the introduction of highly
stable sc and DS2-disulﬁde mutations into bRSV F resulted in even
lower expression yields, necessitating extensive screening of
nearly 100 designs. Our results suggest that the transplantation
of stabilizing pre-F mutations even for relatively closely related
paramyxoviruses faces hurdles of antigenic stability and expres-
sion yield. Nevertheless, our design efforts for bRSV F resulted in a
highly stable immunogen recognized by pre-F-speciﬁc RSV F
antibodies that was immunogenic in mice and protective in
calves.
Remarkably, the neutralization titers elicited by the DS2
immunogen in calves (geometric mean 21,849 at week 8) were
>100 higher than those elicited by the post-F immunogen. This is
consistent with neutralization titers elicited by hRSV F DS2
immunogens in mice which were also >100 higher than post-F
elicited titers.18 In contrast, the overall immunogenicities of pre-F
DS2 and post-F bRSV F immunogens as measured by ELISA were
statistically comparable (Supplementary Fig. 3), suggesting that
differences in elicited neutralization titers were due to differences
in antibody neutralization potency, which likely reﬂects the
availability and stability of neutralization-sensitive epitopes on
the immunogens. The epitopes recognized by the potent
neutralizing antibodies D25 and AM14 are present exclusively in
the pre-F conformation33, whereas epitopes for less potent
neutralizing antibodies such as Pz, (10–100 less potent),17 are
present in both the pre-F and post-F conformations. The low
neutralization titers induced by post-F bRSV F are not unprece-
dented as a recent study has reported similarly low values.18
Moreover, there is a signiﬁcant correlation between pre-F stability
and the ability to elicit neutralizing antibodies.17, 18 Thus, it is not
surprising that DS-Cav1 versions of hRSV F and bRSV F, which are
less thermostable than the DS2 versions, consistently elicit
neutralization titers lower than DS2 pre-F immunogens17, 18
(Supplementary Table 7). Interestingly, two recent human clinical
trials evaluating pre-F and post-F versions of recombinant hRSV F,
respectively, revealed roughly comparable neutralization titers for
similar time points and doses.35, 36 However, the post-F
immunogen was presented as a nanoparticle, which may have
enhanced its immunogenicity, whereas the pre-F immunogen was
not in a nanoparticle format and its degree of pre-F stabilization
was unclear. Finally, one caveat that makes it difﬁcult to directly
compare multiple immunogenicity studies in general is that
differences in the neutralization assay, including detection
method, target cell line, and the virus strain can affect the
dynamic range of the assay results.
Upon challenge with the heterologous bRSV Snook strain,
signiﬁcant differences were observed between the DS2-
immunized and post-F-immunized groups of calves. Vaccination
with the DS2 immunogen protected four out of ﬁve calves against
clinical signs of disease and pulmonary inﬂammation induced by
bRSV infection and appeared to protect all immunized calves
against bRSV replication in both the upper and lower respiratory
tract. However, an increase in RR on days 5 and 6, together with
the presence of macroscopic lung lesions, and a high proportion
of neutrophils in the BAL of one of the calves vaccinated with the
DS2 immunogen suggests a lack of protection in this animal from
bRSV, and the failure to isolate bRSV from this animal could have
been due to in vitro neutralization of virus infectivity. Vaccination
with a post-F immunogen also appeared to reduce the severity of
clinical signs of disease, the extent of macroscopic lung lesions,
and replication of bRSV in the lung. However, protection against
bRSV infection in calves vaccinated with post-F immunogen did
not appear to be as great as that in animals vaccinated with the
DS2 immunogen.
Intramuscular vaccination is unlikely to have induced a mucosal
immune response which restricted virus infection at the portal of
entry. Therefore, the failure to isolate bRSV from the nasopharynx
of DS2-immunized calves may have been due to transudation of
serum antibodies. However, the absence of a pulmonary
inﬂammatory response in the majority of DS2-immunized calves
indicated bRSV replication to be severely restricted in the lower
respiratory tract.
Importantly, vaccination with the DS2 immunogen did not
prime for enhanced respiratory disease (ERD) when calves were
challenged, 4 weeks after vaccination. Furthermore, pulmonary
eosinophilia, which has been associated with vaccine-ERD in
infants, calves, and mice,11, 37, 38 was not seen in either group of
vaccinated calves, even though bRSV was isolated from the BAL of
all calves that had been vaccinated with post-F bRSV F. ERD in
mice and cotton rats vaccinated with formalin-inactivated virus or
puriﬁed F protein is associated with virus replication in the lungs,
induction of a Th2-biased cytokine response and low afﬁnity,
poorly neutralizing antibodies.38–40 Although the T-cell response
was not analyzed in the present study, the MontanideTM ISA 71G
adjuvant used was designed to increase Th1 responses in
veterinary species.
There is still a great need for an effective commercial bRSV
vaccine, as evidenced by the considerable annual economic and
production losses to the cattle industry from bRSV.3 Furthermore,
a recent meta-analysis of vaccination studies reported no
signiﬁcant difference in mortality and morbidity risk between
unvaccinated calves and those vaccinated with modiﬁed live bRSV
vaccines and mixed results for inactivated bRSV vaccines.41 The
robust protection of calves from bRSV elicited by vaccination with
a pre-F-stabilized DS2 immunogen provides proof-of-concept that
such a structurally engineered immunogen can be effective
against RSV infection in a native host. Moreover, the close
evolutionary relationship between bRSV and hRSV suggests that a
human DS2 immunogen could similarly protect humans from
hRSV. Indeed, recently engineered hRSV DS2-stabilized pre-F
immunogens have also been reported to elicit high-neutralization
titers to hRSV in mice.18 Although there are theoretical concerns
that subunit vaccines could prime for ERD in hRSV-naive infants,
DS2 was not observed to induce ERD in any immunized calves and
recombinant viral vectors expressing DS2 could be delivered at a
mucosal surface where it would be expected to prime both CD4
and CD8 T cells, thus mitigating the potential for ERD, as well as
inducing high levels of neutralizing antibodies. Vaccines consist-
ing of post-F hRSV F protein are currently in development to boost
immunity in the elderly,42 and to vaccinate pregnant women in
order to boost protection against hRSV in young infants.43
However, the demonstration that pre-F-stabilized DS2 bRSV F
induces levels of neutralizing antibodies in calves that are more
than 100-fold greater than those induced by post-F immunogens
indicates that signiﬁcantly higher levels of protection may be
achievable in humans through vaccination with DS2-like hRSV F
immunogens. Together, our results support the further evaluation
of vaccines based on DS2-stabilized forms of RSV F in both
humans and cattle.
MATERIALS AND METHODS
Protein expression, puriﬁcation
RSV F variants were expressed by transient transfection of Expi293F cells
(Thermo Fisher Scientiﬁc, MA) using 293Fectin (Thermo Fisher Scientiﬁc,
MA). Cell culture supernatants were harvested 5 days post transfection and
centrifuged at 10,000×g to remove cell debris. The supernatants were
sterile-ﬁltered, and RSV F variants were puriﬁed by nickel (Roche) and
Strep-Tactin (iba) afﬁnity chromatography followed by SEC. The foldon
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domain was removed only when proteins were prepared for animal
immunization. The C-terminal tags were removed from the variants by
digestion with 2 U/ml restriction-grade thrombin (Novagen) overnight at 4
°C. The bRSV F glycoprotein with puriﬁcation tags removed were then
puriﬁed by a second round of SEC in PBS.
Expression and puriﬁcation of antibodies and antigen-binding
fragments (Fabs)
Antibodies were expressed by transient co-transfection of Expi293F cells
with both heavy- and light-chain plasmids using 293fectin. Cell super-
natants were harvested after 4–5 days and passed over Protein A agarose
(GE Healthcare, PA). Bound antibodies were washed with PBS and eluted
with IgG elution buffer (Pierce, IL) into 1/10th volume of 1 M Tris-HCl pH
8.0. Fabs were generated by digesting the IgG with Lys-C or HRV3C
protease,17 and the cleaved Fc region was removed by passing the mixture
over Protein A agarose. Final puriﬁcation of Fabs was performed by SEC.
Antigenic screening of bRSV F immunogens
Initial assessment of all constructs were performed using a 96-well
microplate format for high throughput expression followed by an ELISA-
based antigenic evaluation as described previously.17 Brieﬂy, 24 h prior to
transfection HEK 293T cells (Thermo Fisher Scientiﬁc, MA) were seeded in
each well of a 96-well microplate at a density of 2.5×105 cells/ml in
expression medium (high glucose Dulbecco's modiﬁed Eagle medium
(DMEM) supplemented with 10% ultra-low IgG fetal bovine serum and 1×-
non-essential amino acids), and incubated at 37 °C, 5% CO2 for 20 h.
Plasmid DNA and TrueFect-Max (United BioSystems, MD) were mixed and
added to the growing cells, and the 96-well plate incubated at 37 °C, 5%
CO2. One day post transfection, enriched medium (high glucose DMEM
plus 25% ultra-low IgG fetal bovine serum, 2× nonessential amino acids, 1×
glutamine) was added to each well, and the 96-well plate was returned to
the incubator for continuous culture. Five days post transfection super-
natants with the expressed bRSV F variants were harvested and tested by
ELISA for binding to D25, MPE8 and Mz antibodies using Ni2+-nitrilo-
triacetic acid (NTA) microplates.
RSV F antigenic characterization
A fortéBio Octet Red384 instrument was used to measure binding kinetics
of RSV F variants to antibodies that target the pre-F or post-F form (D25,
AM14, MPE8, and Mz). All assays were performed with agitation set to
1000 rpm in PBS supplemented with 1% bovine serum albumin (BSA) to
minimize nonspeciﬁc interactions. The ﬁnal volume for all solutions was 50
μl/well. Assays were performed at 30 °C in tilted black 384-well plates
(Geiger Bio-One). Ni-NTA sensor tips were used to capture relevant RSV F
variants. Typical capture levels for each loading step were between 1.4 and
1.5 nm, and variability within a row of eight tips did not exceed 0.1 nm for
each of these steps. Biosensor tips were equilibrated for 120 s in PBS + 1%
BSA prior to loading bRSV F variants. Biosensor tips were then equilibrated
for 120 s in PBS + 1% BSA prior to measuring association with Fabs in
solution (0.007 μM to 1.0 μM) for 300 s; Fabs were then allowed to
dissociate for 300–1200 s depending on the observed dissociation rate.
Parallel correction to subtract systematic baseline drift was carried out by
subtracting the measurements recorded for a loaded sensor incubated in
PBS + 1% BSA. Data analysis and curve ﬁtting were carried out using Octet
software, version 9.0. Experimental data were ﬁtted with the binding
equations describing a 1:1 interaction. Global analysis of the data sets
assuming reversible binding (full dissociation) were carried out using
nonlinear least-squares ﬁtting allowing a single set of binding parameters
to be obtained simultaneously for all of the concentrations used in each
experiment.
Physical stability of RSV F variants
To assess the physical stability of the pre-F conformation of designed bRSV
F glycoproteins under various stress conditions, we treated the proteins
with a variety of pharmaceutically relevant stresses such as extreme pH,
high temperature, low and high osmolarity, and repeated freeze/thaw
cycles while at a concentration of 50 μg/ml. The physical stability of treated
bRSV F variants was evaluated by the preservation of antigenic site Ø after
treatment as assessed by binding of the site Ø-speciﬁc antibody D25. In pH
treatments, the bRSV F glycoprotein solution was adjusted to pH 3.5 and
pH 10 with appropriate buffers and incubated at room temperature for 60
min and subsequently neutralized to pH 7.5. Temperature treatments were
carried out by incubating the bRSV F glycoprotein solutions at 50 °C and
70 °C for 60min in a PCR cycler with heated lid. In osmolarity treatments,
bRSV F glycoprotein solutions originally containing 150mM NaCl were
either diluted with 2.5 mM Tris buffer (pH 7.5) to an osmolarity of 10mM
NaCl or adjusted with 4.5 M MgCl2 to a ﬁnal concentration of 3.0 M MgCl2.
Protein solutions were incubated for 60min at room temperature and then
returned to 150mM salt by adding 5.0 M NaCl or dilution with 2.5 mM Tris
buffer, respectively, and concentrated to 50 μg/ml. The freeze/thaw
treatment was carried out by repeatedly freezing bRSV F glycoprotein
solutions in liquid nitrogen and thawing at 37 °C ten times in the presence
of 10% glycerol. All bRSV F glycoproteins were diluted to 40 μg/ml with
PBS + 1% BSA, and their ability to bind D25 Fab was measured with an
Octet instrument using the protocol described above. The degree of
physical stability is reported as the ratio of steady state D25-binding level
before and after stress treatment.
Negative stain EM
Samples were diluted to approximately 0.01 mg/ml, adsorbed to freshly
glow-discharged carbon-coated grids, rinsed with several drops of buffer
containing 10mM HEPES, pH 7.0, and 150mM KCl, and stained with 0.75%
uranylformate. Images were recorded on an FEI T20 microscope with a 2k
× 2k Eagle CCD camera at a pixel size of 2.2 Å. Reference-free 2D
classiﬁcation and averaging were performed with EMAN244 and SPIDER45.
Crystallization and X-ray data collection of pre-F-stabilized bRSV F
proteins
Crystallization conditions were screened by vapor diffusion using a
Mosquito crystallization robot (TTP labtech) that generated sitting drops
at 20 °C by mixing 0.2 μl of bRSV immunogens with 0.2 μl of reservoir
solution. Optimized crystals for data collection were grown by manually
setting up hanging drops combining 0.5 µl protein with 0.5 µl of reservoir
solution. ATue51908 DS-Cav1 crystals were grown in 12% (w/v) PEG 3350,
and 0.1 M sodium acetate pH 5.5, and DS2-v1 (391-2 sc9 DS-Cav1 Q98C
Q361C) crystals were grown in 0.9 M K/Na tartrate, 0.16 M Li2SO4, and 0.1 M
CHES pH 9.5. Prior to data collection, ATue51908 DS-Cav1 crystals were
transferred to 15% (v/v) 2R,3R-butanediol, 18% (w/v) PEG 3350, and 0.1M
sodium acetate pH 5.5 and DS2-v1crystals were transferred to 15% (v/v)
2R,3R-butanediol, 1.3 M K/Na tartrate, 0.16 M Li2SO4, and 0.1 M CHES pH 9.5
followed by ﬂash freezing in liquid nitrogen. X-ray diffraction data were
collected at a wavelength of 1.00 Å at the SER-CAT beamline ID-22
(Advanced Photon Source, Argonne National Laboratory).
Structure determination, reﬁnement, and analysis of pre-F-
stabilized bRSV F
Diffraction data were integrated and scaled with the HKL2000 suite,46 and
a molecular replacement solutions for both structures were obtained by
PHASER47 using the pre-F RSV F structure (PDB ID: 4MMS17) as a search
model. Manual model building was carried out using COOT,48 with
secondary structure elements built ﬁrst. Reﬁnement of individual
coordinates, TLS parameters, and individual B-factors was performed in
PHENIX.49 Final data collection and reﬁnement statistics are presented in
Supplementary Table 6. All structural images were created using PyMol
(The PyMol Molecular Graphics System, version 1.1; Schrödinger, LLC).
Mouse immunizations
All mouse experiments were reviewed and approved by the Animal Care
and Use Committee of the Vaccine Research Center, NIAID, NIH, under
animal protocol 13–454, and all animals were housed and cared for in
accordance with local, state, federal, and institute policies in an American
Association for Accreditation of Laboratory Animal Care (AAALAC)-
accredited facility at the NIH. Mice were randomized into groups of ten
and these groups were not blinded to the investigators. As in previous
experiments,17 hybrid female mice that were the ﬁrst ﬁlial offspring of a
cross between BALB/cJ females (C) and C57BL/6J males (B6) (The Jackson
Laboratory) known as CB6F1/J at ages 6 weeks to 12 weeks were
intramuscularly injected with RSV F immunogens at week 0 and week 3.
The frozen RSV F variant immunogen proteins were thawed on ice and
mixed with ﬁvefold w/w poly I:C (Invivogen) adjuvant (that is, 10 μg RSV F,
50 μg Poly I:C per animal per immunization), with injections taking place
within 1 h of immunogen:adjuvant preparation. No adverse effect from
immunization was observed. Blood was collected at least 3 days before
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immunization, and at week 2, week 5, and week 7 post initial
immunization.
bRSV neutralization assays
bRSV microneutralization assay was performed using BT cells (ATCC
CRL1390) and 500–1000 TCID50 (50% tissue culture infectious doses) of
bRSV, strain 375 (ATCC VR1339). Brieﬂy, immune sera were serially diluted
in quadruplicates prior to mixing with 500–1000 TCID50 of bRSV for 1 h at
37 °C in a humidiﬁed 5% CO2 atmosphere prior to addition to monolayers
of BT cells seeded the day before at 8000 cells/well. Cells were then
incubated for 7 days, ﬁxed with 70% methanol, stained with 1% crystal
violet and examined at the microscope for syncytia formation and
cytopathic effect (CPE). Neutralizing titer was deﬁned as the reciprocal of
the highest sera dilution at which the infectivity of bRSV was completely
neutralized in 50% of the wells. Infectivity was identiﬁed by the presence
of CPE and syncytia on day 7, and the titer was calculated by the Reed-
Muench method.
ELISA-binding assays
A standard ELISA was used to determine binding of immune sera to bRSV
pre- and post-bRSV F proteins. Brieﬂy, ELISA plates were coated with
antigens at 5 µg/ml, blocked with 1% BSA in PBS, incubated with serial
dilutions of sera and washed. Bound mAbs were detected by incubation
with AP-conjugated Goat Anti-Mouse adsorbed against human IgG
(Southern Biotech) or goat anti-bovine IgG (Southern Biotech). Plates
were then washed, substrate (4-Nitrophenyl phosphate disodium salt
hexahydrate, Sigma) was added and plates were read at 405 nm. The
relative titer of sera binding to respective coated antigens were
determined by measuring the concentration of each serum required to
achieve 50% binding relative to the maximum (ED50). The ED50 values were
calculated by interpolation of binding curves ﬁtted with a four-parameter
nonlinear regression with a variable slope.
Calf immunization
The calf experiment was performed under the regulations of the Home
Ofﬁce Scientiﬁc Procedures Act (1986) of the United Kingdom. The study
had been reviewed and approved by the Animal and Plant Health
Agency (APHA) Ethical Review Committee. Calve groups were not
blinded to the investigators. Male calves were obtained from local farms
and were removed from their mothers at birth to ensure that they did
not receive any colostrum and transported to APHA at ~1 day of age.
Calves were bled on arrival at APHA and were fed 250 ml of colostrum,
48 h after birth, in order produce calves with little or no maternally
derived bRSV-speciﬁc serum antibodies. Sera obtained before and after
colostrum intake was analyzed for bRSV-speciﬁc and prefusion bRSV F
protein-speciﬁc antibodies by ELISA.50 All but two calves were free from
bRSV-speciﬁc serum antibodies. Calves were allocated to three groups of
ﬁve to give groups matched for calf age, and the two animals with
maternally derived bRSV-speciﬁc antibodies were allocated to the
control group. Calves were 3 to 6-weeks-old at the time of vaccination.
The frozen bRSV F proteins, pre-F (DS2) and post-F (391-2 post-F) were
thawed on ice and mixed with MontanideTM ISA71 VG (Seppic, France) in
a water in oil emulsion in a ratio of 70:30 adjuvant to aqueous phase.
Calves were inoculated intramuscularly with 50 μg protein in a volume of
2 ml on two occasions 4 weeks apart. As controls, calves were inoculated
with 2 ml PBS in ISA71 VG. Vaccinations took place within 3 h of
immunogen:adjuvant preparation. Calves developed a transient fever 24
h after vaccination and no or only mild diffuse swelling at the injection
sites. Calves were bled at deﬁned time points for analysis of bRSV-
speciﬁc serum antibody responses.
Calf challenge virus
Virulent bRSV used to challenge calves consisted of BAL prepared from a
gnotobiotic calf inoculated 6 days previously with the Snook strain of
bRSV, which had been passaged on four previous occasions in gnotobiotic
or speciﬁc pathogen free calves. The BAL was free from other viruses,
mycoplasmas, and bacteria as assessed by inoculation of tissue culture
cells, mycoplasmal or bacterial media. Virus titers were determined by
plaque assay on fetal calf kidney cells.
Calf challenge
Four weeks after the last vaccination, calves were challenged by intranasal
and intratracheal administration of 104 pfu of bRSV, Snook strain, in BAL.50
Following bRSV challenge, nasopharyngeal swabs were obtained daily to
monitor bRSV excretion, and calves were examined daily for clinical signs
of disease. The severity of disease was given a score as shown in
Supplementary Table 12. The clinical scores are deﬁned in Supplementary
Table 13. Calves were euthanized 6 days after challenge to determine the
extent of gross pneumonic consolidation and the extent of virus infection
in the lower respiratory tract as described previously.50 Titers of virus in the
trachea were determined by scraping the epithelium from a piece of
trachea approximately 3 cm long into 2ml of Hanks balanced salt solution
(Sigma) containing 1% BSA (Sigma). The apical and cardiac lung lobes were
clamped and the lungs lavaged with ~1 liter of PBS to obtain
bronchalveolar lavage (BAL). Cytospin preparations of BAL cells were ﬁxed
and stained with Diff Quik (Thermo Fisher Scientiﬁc) and differential cell
counts made using oil immersion microscopy. Samples of lung taken from
three different apical lung lobes were homogenized to give a 20% w/v
suspension. Lung tissue for histology was also taken from three different
apical lobes and ﬁxed in 10% neutral buffered formalin, parafﬁn wax
embedded and sections were stained with hematoxylin and eosin.
Statistical analysis
Statistical analyses were performed using two-tailed Mann–Whitney tests
with GraphPad Prism 6.0 software (La Jolla, CA). Differences were
considered statistically signiﬁcant at P < 0.05.
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